Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16305898 | 1.00 | POLB (0.40) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL16255808 | 0.92 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL19112371 | 0.92 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL16305897 | 0.92 | POLB (0.39) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL13523539 | 0.91 | POLB (0.41) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL13523533 | 0.91 | POLB (0.41) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL13523797 | 0.91 | POLB (0.41) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL19112314 | 0.91 | POLB (0.38) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL19112312 | 0.91 | POLB (0.38) | POLBMEN1USP2KMT2AHSD17B10 | |
| SCHEMBL13592886 | 0.91 | POLB (0.41) | POLBMEN1USP2KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708357-B2 | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | Riboscience, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708357-B2 | 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | Riboscience, LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9694028-B2 | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | RIBOSCIENCE LLC (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2794628-B1 | 4'-AZIDO-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160220596-A1 | 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2016-08-04 | — | — | US | disclosed |
| US-9249176-B2 | 4′-azido, 3′-deoxy-3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication | RIBOSCIENCE LLC (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2014-12-18 | — | — | US | disclosed |
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC | 2014-12-18 | — | — | US | disclosed |
| WO-2014193663-A1 | 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES | RIBOSCIENCE LLC (US) | 2014-12-04 | — | — | WO | disclosed |
| US-20140341848-A1 | 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RIBOSCIENCE LLC (US) | 2014-11-20 | — | — | US | disclosed |
| WO-2013092447-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140369959-A1 | 4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | RNGTT, NSUN2, NSUN3 | POLB 217/4885MEN1 4587/4885USP2 3927/4885 |
| US-20160220596-A1 | 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | EIF2AK2, NSUN2, RNGTT | POLB 111/4885MEN1 4813/4885USP2 2583/4885 |
| US-20140341848-A1 | 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | EIF2AK2, NSUN2, RNGTT | POLB 111/4885MEN1 4813/4885USP2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.